Transgenic Mouse Model Spy1A MMTV Promoter Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of breast cancer molecular signatures and biochemical pathways is incomplete, hindering the identification of effective therapeutic approaches due to the heterogeneous nature of breast cancer, which necessitates a more comprehensive understanding of the molecular mechanisms underlying mammary tumorigenesis.
Innovation Solution
A transgenic non-human animal model is developed to overexpress Spy1A under the control of a MMTV promoter, leading to cancer development, particularly breast cancer, allowing for the study and potential treatment of cancer through the regulation of cell cycle control and proliferation mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a transgenic animal model is developed to overexpress Spy1A under MMTV promoter control, then the ability to study breast cancer molecular mechanisms is improved, but the complexity of the research system increases
Solution Approach 1:
The patent uses the MMTV promoter as an intermediary element to control Spy1A expression specifically in mammary tissue. This promoter acts as a mediator between the transgene and the target tissue, enabling selective overexpression of Spy1A in the mammary gland without requiring complex tissue-specific regulatory systems. The MMTV promoter has been well-characterized for its ability to drive expression in mammary epithelial cells, thus simplifying the overall transgenic system while maintaining high reliability for breast cancer studies.
2Loss of information
If Spy1A overexpression is used to promote cell proliferation and tumorigenesis, then the understanding of cancer development mechanisms is improved, but the ethical considerations and regulatory hurdles increase
Solution Approach 1:
The patent employs parameter changes by controlling the expression level of Spy1A through the MMTV promoter system. By regulating the transcriptional activity of the promoter, the model achieves controlled overexpression of Spy1A that promotes tumorigenesis in a dose-dependent manner. This allows researchers to study cancer development at different stages and intensities, providing comprehensive insights into cancer mechanisms while maintaining可控 expression levels that can be monitored and adjusted.
3Productivity
If the transgenic model is designed to develop cancer rapidly, then the time required for therapeutic screening is reduced, but the physiological relevance of the cancer model may be compromised
Solution Approach 1:
The patent applies local quality by restricting Spy1A overexpression specifically to mammary tissue through the MMTV promoter, rather than systemic overexpression throughout the body. This localized expression approach accelerates mammary tumorigenesis in the target tissue while minimizing off-target effects and maintaining physiological relevance in other organ systems. The MMTV promoter ensures that Spy1A is expressed only in mammary epithelial cells, creating a more physiologically accurate model of breast cancer development compared to ubiquitous overexpression systems.
Data Source
AI summary
In one aspect, the invention provides a transgenic non-human animal model having germ cells and somatic cells containing an endogenous MMTV-SV40-Spy1A gene sequence introduced into said animal model or an ancestor of said animal model at an embryonic stage, wherein said gene sequence comprises a mouse mammary tumor virus gene (MMTV), a functionally disrupted SV40 gene (SV40) and a human Spy1A gene. In another aspect, the present invention provides a transgenic non-human animal model whose germ cells and somatic cells contain an endogenous Spy1A-pTRE-Tight gene sequence introduced into said animal model or an ancestor of said animal model at an embryonic stage. Preferably, the Spy1A-pTRE-Tight animal model expresses the Spy1A gene and develop cancer, preferably breast cancer, when administered with tetracycline, preferably doxycycline.